Education
About Us
Working with TipRanks
Follow Us
Sensei Biotherapeutics (SNSE)
NASDAQ:SNSE
SNSE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.25 - $1.94
Previous CloseN/A
Volume8.76M
Average Volume (3M)5.44M
Market Cap
$8.70M
Enterprise Value-$25.16M
Total Cash (Recent Filing)$10.96M
Total Debt (Recent Filing)$5.64M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
May 13, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding25,208,069
10 Day Avg. Volume16,181,839
30 Day Avg. Volume5,444,309
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)33.31
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-2.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.87
Forecast
1Y Price Target
$4.00Price Target Upside1150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Sensei Biotherapeutics News
PremiumCompany Announcements
Sensei Biotherapeutics Reports Promising 2024 Results
PremiumCompany Announcements
Sensei Biotherapeutics Reports Promising Phase 1/2 Trial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial DevelopmentsSensei Biotherapeutics has reported compelling preliminary dose expansion data for solnerstotug in patients with advanced solid tumors, showing a high disease control rate.
Financial OutlookSensei's cash runway has been extended into 2Q26 due to corporate restructuring.
Regulatory ProgressSNS-101 could potentially be the first anti-VISTA monoclonal antibody approved as a therapeutic agent, with an anticipated launch in 2029.
Bears Say
Clinical Efficacy ConcernsNo complete or partial responses were observed in patients with 'cold' tumors, as expected, indicating limited efficacy in this group.
EarningsSensei reported 4Q24 EPS of ($0.31), compared to an estimate of ($0.29).
Regulatory ChallengesThe anticipated data update for the SNS-101 study has been delayed to 1H25, as the company seeks more duration data.
---
Ownership Overview
31.38% Insiders
3.11% Mutual Funds
4.68% Other Institutional Investors
58.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SNSE FAQ
What was Sensei Biotherapeutics’s price range in the past 12 months?
Sensei Biotherapeutics lowest stock price was $0.25 and its highest was $1.94 in the past 12 months.
What is Sensei Biotherapeutics’s market cap?
Sensei Biotherapeutics’s market cap is $8.70M.
When is Sensei Biotherapeutics’s upcoming earnings report date?
Sensei Biotherapeutics’s upcoming earnings report date is May 13, 2025 which is in 38 days.
How were Sensei Biotherapeutics’s earnings last quarter?
Sensei Biotherapeutics released its earnings results on Mar 28, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.283 by -$0.027.
Is Sensei Biotherapeutics overvalued?
According to Wall Street analysts Sensei Biotherapeutics’s price is currently Undervalued.
Does Sensei Biotherapeutics pay dividends?
Sensei Biotherapeutics does not currently pay dividends.
What is Sensei Biotherapeutics’s EPS estimate?
Sensei Biotherapeutics’s EPS estimate is -0.22.
How many shares outstanding does Sensei Biotherapeutics have?
Sensei Biotherapeutics has 25,208,069 shares outstanding.
What happened to Sensei Biotherapeutics’s price movement after its last earnings report?
Sensei Biotherapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.283. Following the earnings report the stock price went up 18.605%.
Which hedge fund is a major shareholder of Sensei Biotherapeutics?
Currently, no hedge funds are holding shares in SNSE
---
Company Description
Sensei Biotherapeutics
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
---
SNSE Stock 12 Month Forecast
Average Price Target
$4.00
▲(1150.00% Upside)
Technical Analysis
Fate Therapeutics
―
Sorrento Therapeutics
―
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Immatics
―
Best Analysts Covering SNSE
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-40.40%
initiated a buy rating 10 months ago
Copying Samantha Semenkow's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.40% per trade.
---